Biogen Inc. (BIIB)
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position
Italy's antitrust authority said on Wednesday it had opened an investigation into drug maker Biogen Italia and its parent Biogen over alleged abuse of dominant position.
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
U.S. Food & Drug Administration (FDA) events crystallize the risk/reward thesis for many biotechnology stocks, and Biogen Inc.'s NASDAQ: BIIB latest Alzheimer's update shows why that trade can turn quickly.
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
Biogen and Denali Therapeutics said on Thursday they will discontinue development of their Parkinson's drug after it failed to meet the main goal in a mid-to-late stage study.
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity
Biogen Inc. is upgraded from Sell to Hold, reflecting recent strategic moves and a modest rebound despite persistent structural challenges. BIIB's acquisition of Apellis for ~$5.6bn adds near-term revenue and nephrology expansion, though realizing a robust kidney franchise remains uncertain. Q1 results were mixed: MS revenues are stable, but long-term decline looms, while new product launches are unlikely before 2028/2029.
